Dr. Raphael Schiffmann, M.D
NPI: 1700037603
Total Payments
$122,917
2024 Payments
$14,385
Companies
30
Transactions
168
Payment Breakdown by Category
Consulting$40,953 (33.3%)
Travel$37,596 (30.6%)
Other$21,232 (17.3%)
Research$20,078 (16.3%)
Food & Beverage$3,021 (2.5%)
Education$37.65 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $40,953 | 20 | 33.3% |
| Travel and Lodging | $37,596 | 19 | 30.6% |
| Unspecified | $20,078 | 18 | 16.3% |
| Honoraria | $18,736 | 6 | 15.2% |
| Food and Beverage | $3,021 | 95 | 2.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,496 | 9 | 2.0% |
| Education | $37.65 | 1 | 0.0% |
Payments by Type
General
$102,839
150 transactions
Research
$20,078
18 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amicus Therapeutics, Inc. | $48,885 | 24 | $0 (2023) |
| GENZYME CORPORATION | $35,900 | 49 | $0 (2024) |
| Chiesi USA, Inc. | $26,458 | 14 | $0 (2024) |
| Shire North American Group Inc | $3,861 | 14 | $0 (2019) |
| PFIZER INC. | $1,568 | 3 | $0 (2017) |
| Mallinckrodt LLC | $1,107 | 3 | $0 (2018) |
| Vertex Pharmaceuticals Incorporated | $1,050 | 2 | $0 (2023) |
| SANOFI-AVENTIS U.S. LLC | $772.08 | 2 | $0 (2019) |
| Kyowa Kirin, Inc. | $600.00 | 1 | $0 (2023) |
| Dr.Reddy's Laboratories,Inc. | $525.00 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $14,385 | 21 | Chiesi USA, Inc. ($12,853) |
| 2023 | $13,247 | 10 | Chiesi USA, Inc. ($9,351) |
| 2022 | $138.96 | 3 | ARGENX US, INC. ($100.46) |
| 2021 | $3,395 | 2 | GENZYME CORPORATION ($2,920) |
| 2020 | $8,407 | 24 | GENZYME CORPORATION ($7,665) |
| 2019 | $64,890 | 59 | Amicus Therapeutics, Inc. ($46,310) |
| 2018 | $2,454 | 12 | Mallinckrodt LLC ($1,050) |
| 2017 | $16,001 | 37 | GENZYME CORPORATION ($9,977) |
All Payment Transactions
168 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Takeda Pharmaceuticals U.S.A., Inc. | HYQVIA (Biological) | Food and Beverage | In-kind items and services | $18.50 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | Chiesi USA, Inc. | ELFABRIO (Drug) | Honoraria | Cash or cash equivalent | $3,327.00 | General |
| Category: ERT FOR FABRY DISEASE | ||||||
| 11/21/2024 | Chiesi USA, Inc. | ELFABRIO (Drug) | Travel and Lodging | Cash or cash equivalent | $303.00 | General |
| Category: ERT FOR FABRY DISEASE | ||||||
| 10/31/2024 | Chiesi USA, Inc. | — | Honoraria | Cash or cash equivalent | $4,840.00 | General |
| 10/31/2024 | Chiesi USA, Inc. | — | Travel and Lodging | Cash or cash equivalent | $2,086.55 | General |
| 10/31/2024 | Chiesi USA, Inc. | ELFABRIO (Drug) | Honoraria | Cash or cash equivalent | $1,513.00 | General |
| Category: ERT FOR FABRY DISEASE | ||||||
| 10/31/2024 | Chiesi USA, Inc. | — | Food and Beverage | Cash or cash equivalent | $111.65 | General |
| 10/17/2024 | Chiesi USA, Inc. | ELFABRIO (Drug) | Honoraria | Cash or cash equivalent | $605.00 | General |
| Category: ERT FOR FABRY DISEASE | ||||||
| 09/10/2024 | Lilly USA, LLC | EMGALITY (Drug), REYVOW, KISUNLA | Food and Beverage | In-kind items and services | $15.41 | General |
| Category: Neuroscience | ||||||
| 08/14/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $54.85 | General |
| 08/13/2024 | Lilly USA, LLC | EMGALITY (Drug), REYVOW, KISUNLA | Food and Beverage | In-kind items and services | $20.07 | General |
| Category: Neuroscience | ||||||
| 08/01/2024 | Chiesi USA, Inc. | ELFABRIO (Drug) | Food and Beverage | Cash or cash equivalent | $35.95 | General |
| Category: ERT FOR FABRY DISEASE | ||||||
| 07/01/2024 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,250.00 | General |
| 05/14/2024 | Lilly USA, LLC | AMYVID (Drug) | Food and Beverage | In-kind items and services | $17.63 | General |
| Category: Neuroscience | ||||||
| 04/30/2024 | GENZYME CORPORATION | FABRAZYME (Biological) | Food and Beverage | In-kind items and services | $43.50 | General |
| Category: Genetic Disease | ||||||
| 04/25/2024 | Chiesi USA, Inc. | ELFABRIO (Drug) | Food and Beverage | Cash or cash equivalent | $30.62 | General |
| Category: ERT FOR FABRY DISEASE | ||||||
| 04/10/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $27.80 | General |
| Category: Neurology | ||||||
| 03/20/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $24.91 | General |
| Category: Neurology | ||||||
| 03/12/2024 | Lilly USA, LLC | EMGALITY (Drug), REYVOW | Food and Beverage | In-kind items and services | $17.38 | General |
| Category: Neuroscience | ||||||
| 03/11/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $18.84 | General |
| Category: Immunology | ||||||
| 02/14/2024 | Lilly USA, LLC | EMGALITY (Drug), AMYVID, REYVOW | Food and Beverage | In-kind items and services | $22.88 | General |
| Category: Neuroscience | ||||||
| 11/30/2023 | Chiesi USA, Inc. | ELFABRIO (Drug) | Honoraria | Cash or cash equivalent | $4,821.00 | General |
| Category: ERT FOR FABRY DISEASE | ||||||
| 11/28/2023 | GENZYME CORPORATION | FABRAZYME (Biological), NEXVIAZYME | Food and Beverage | In-kind items and services | $25.26 | General |
| Category: Genetic Disease | ||||||
| 10/25/2023 | Kyowa Kirin, Inc. | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 10/19/2023 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $575.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| GZ/SAR402671 in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 (LEAP) | GENZYME CORPORATION | $13,329 | 8 |
| NONE | Chiesi USA, Inc. | $3,740 | 1 |
| A 52-week two-part, open-label, multicenter, multinational study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of GZ-SAR402671 in combination with Cerezyme | GENZYME CORPORATION | $1,764 | 5 |
| A 208-week three-part, open-label, multicenter, multinational study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of GZ/SAR402671 in combination with Cerezy | GENZYME CORPORATION | $765.00 | 2 |
| A 208-week three-part, open-label, multicenter, multinational study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of GZ-SAR402671 in combination with Cerezyme in adult patients with Gaucher disease Type 3 | GENZYME CORPORATION | $480.00 | 2 |
About Dr. Raphael Schiffmann, M.D
Dr. Raphael Schiffmann, M.D is a Neurology with Special Qualifications in Child Neurology healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/09/2008. The National Provider Identifier (NPI) number assigned to this provider is 1700037603.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Raphael Schiffmann, M.D has received a total of $122,917 in payments from pharmaceutical and medical device companies, with $14,385 received in 2024. These payments were reported across 168 transactions from 30 companies. The most common payment nature is "Consulting Fee" ($40,953).
Ad
Practice Information
- Specialty Neurology with Special Qualifications in Child Neurology
- Location Dallas, TX
- Active Since 10/09/2008
- Last Updated 11/22/2010
- Taxonomy Code 2084N0402X
- Entity Type Individual
- NPI Number 1700037603
Products in Payments
- GALAFOLD (Drug) $48,885
- GZ402671 (Drug) $13,329
- ELFABRIO (Drug) $11,536
- NO PRODUCT DISCUSSED (Drug) $10,627
- FABRAZYME (Biological) $3,829
- LAMZEDE (Drug) $3,630
- CERDELGA (Drug) $2,920
- ELELYSO (Drug) $1,568
- ALDURAZYME (Drug) $750.00
- FERRIPROX (Drug) $514.29
- AUBAGIO (Drug) $207.77
- Fycompa (Drug) $152.86
- SOLIRIS (Drug) $148.86
- AMPYRA (Drug) $142.44
- VYVGART (Drug) $100.46
- FABRY-DISEASE (Drug) $96.67
- EMGALITY (Drug) $75.74
- CEREZYME (Drug) $74.48
- VPRIV (Biological) $73.14
- Epidiolex (Drug) $66.47
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology with Special Qualifications in Child Neurology Doctors in Dallas
Roy Elterman, Md, MD
Neurology with Special Qualifications in Child Neurology — Payments: $9.7M
Neurology with Special Qualifications in Child Neurology $9.7M
Mauricio Delgado, M.d, M.D
Neurology with Special Qualifications in Child Neurology — Payments: $99,674
Neurology with Special Qualifications in Child Neurology $99,674
Dr. Steven Sparagana, M.d, M.D
Neurology with Special Qualifications in Child Neurology — Payments: $16,452
Neurology with Special Qualifications in Child Neurology $16,452
Berge Minassian
Neurology with Special Qualifications in Child Neurology — Payments: $5,079
Neurology with Special Qualifications in Child Neurology $5,079
Dr. Deepa Sirsi, Md, MD
Neurology with Special Qualifications in Child Neurology — Payments: $1,867
Neurology with Special Qualifications in Child Neurology $1,867
Charuta Joshi, Mbbs, Md, MBBS, MD
Neurology with Special Qualifications in Child Neurology — Payments: $1,114
Neurology with Special Qualifications in Child Neurology $1,114